Below are the most recent publications written about "Drug Resistance, Neoplasm" by people in Profiles.
-
Gani M, Agostini F, Secco L, De Pino L, Picco R, Licastro D, Tolotto V, D'Este F, Choudhary H, Ferino A, Rapozzi V, Barasa L, Ohta Y, Nakagawa H, Sgarra R, Thompson PR, Xodo LE, Di Giorgio E. PADI-dependent mitochondrial adaptation drives resistance to KRAS inhibitors. Cell Rep. 2026 Oct 27; 45(10):118016.
-
Lero MW, Morgan JS, Card MA, Zhu LJ, Li J, Li R, Bui QT, Mohlmann E, Goel HL, Shaw LM. Insulin receptor substrate 2 (IRS2) confers resistance to PI3K pathway inhibition in PIK3CA mutant breast cancer. J Biol Chem. 2026 Oct; 302(10):113426.
-
Weiss GJ, Loftus JC, Mallery DW, Tran NL. Structure-guided identification and biological evaluation of reversible EGFR C797S inhibitors. Sci Rep. 2026 May 04; 16(1).
-
Specht E, Pakanati L, Wu MJ, Jenkins RW, Effiom DN, Bardeesy N, Bernstein BE, Sade-Feldman M, Lian CG, Boland GM, Torlai Triglia E, Cohen S. Loss of tumor-infiltrating lymphocytes and poor response to immunotherapy in IDH GOF mutant melanoma. JCI Insight. 2026 06 08; 11(11).
-
Kaddoura M, Wiedmeier-Nutor JE, Gupta VA, Jelinek T, Ziccheddu B, Shivaram S, Tang H, Owens RW, Sevcikova T, Fonseca R, Durante M, Diamond B, Zhao L, Zhu YX, Shi CX, Matulis SM, Mitsiades CS, Landgren O, Usmani S, Hajek R, Chesi M, Bergsagel PL, Braggio E, Boise LH, Fonseca R, Kumar S, Maura F, Baughn LB. Genomic mechanisms of resistance to venetoclax in multiple myeloma with t(11;14)(CCND1;IGH). Blood. 2026 Apr 02; 147(14):1598-1610.
-
Hansen DK, Lu X, Castaneda Puglianini O, Zhang E, Usmani SZ, Sachdev R, Perciavalle M, De Wiest D, Huo S, Lee S, Qureshi ZP, Jagannath S. Comparative cost per responder analysis of ciltacabtagene autoleucel and real-world standard of care therapy in patients with lenalidomide-refractory multiple myeloma. Expert Rev Pharmacoecon Outcomes Res. 2026 Mar; 26(3):369-378.
-
Yu JX, Suh JM, Popova KD, Garcia K, Joshi T, Culbertson B, Spinelli JB, Subramanyam V, Lou K, Charbonneau T, Shokat KM, Weissman J, Goodarzi H. The GENEVA platform models tumor mosaicism to reveal variations of responses to KRAS inhibitors and identify improved drug combinations. Nat Cancer. 2026 Mar; 7(3):522-537.
-
Puig N, Leleu X, Lee HC, Davies FE, Hájek R, Hungria V, Thompson MA, Cook G, Ojeda JV, Weisel KC, Berdeja JG, Usmani SZ, Symeonidis A, Nascimento-Ferreira I, Arthur D, Mokrá L, Ren K, Cherepanov D, Terpos E. Comparative Effectiveness and Safety of PI-Rd Triplets in Relapsed/Refractory Multiple Myeloma: INSIGHT-MM Data Analysis. Eur J Haematol. 2026 Apr; 116(4):458-470.
-
Peng M, Lee S, Nair HG, MacGilvary N, Cong K, Kraemer M, Li R, McConnell J, Baer C, Deng B, Zhu L, Cantor SB. RAD51 is chromatin enriched and targetable in BRCA1-deficient cells. Mol Cell. 2025 09 18; 85(18):3373-3387.e6.
-
Xue T, Liu X, Song C, Fei S, Gu J, Han Y, Xing J, Liu X, Liang F, Thompson PR, Zhang X. Citrullination of AKT2 Catalyzed by PAD1 Facilitates the Maintenance of Stemness Characteristics of Ovarian Cancer Stem-Like Cells in Ovarian Cancer. Adv Sci (Weinh). 2025 10; 12(39):e01014.